CardioCell To Pursue Large-Scale Chronic Heart Failure Trial For IV Stem Cell Therapy
Executive Summary
CardioCell has presented data from the first clinical trial to demonstrate the safety and viability of intravenous (IV) ischemia-tolerant mesenchymal stem cells in chronic heart failure patients – dispelling the theory that only large amounts of stem cells delivered directly to the myocardium would achieve improvements in patient outcomes.